Oral GHS-R1a agonist that stimulates appetite, GH/IGF-1 axis and lean body mass.
Reference facts
- Also known as
- ONO-7643, RC-1291, Adlumiz
- Category
- Growth Hormone & Ghrelin
- Mechanism of action
- Oral GHS-R1a agonist that stimulates appetite, GH/IGF-1 axis and lean body mass.
- Targets
- GHS-R1a
- Indications under research or approved
- Cancer cachexia (NSCLC, gastric, pancreatic, colorectal)
- Regulatory status (reference entry)
- Approved Japan (Adlumiz, 2021); FDA CRL 2017
- Half-life
- ~7 hours
- Sequence notes
- Orally active peptidomimetic ghrelin receptor agonist (small molecule with peptide-mimetic backbone).
- Molecular weight (Da)
- 547
- Originator / sponsor
- Helsinn / Ono
- First reported
- 2003
Primary References
Explore research articles about Anamorelin
This is an educational reference, not medical advice. Research findings do not establish safety or efficacy for self-administration. Consult the primary sources for study populations, limitations, and current regulatory status.